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1 |  INTRODUCTION
We set out to experimentally treat restless legs syndrome pa-
tients with preparations of Bryophyllum pinnatum that have 
been proposed to possess sedative and muscle relaxant prop-
erties. The disease courses of our five patients suggest that 
treatment with these preparations (mainly chewable tablets) 
can improve restless legs syndrome and sleep quality.
Restless legs syndrome (RLS) is a neurologic disorder 
characterized by a compelling urge to move one's legs, usu-
ally worsening in the evening and at night.1 The diagnosis is 
done clinically, based on five essential criteria (see Box).1 
Treatment of RLS is challenging. Patients often suffer from 
disturbed quality of life, whereby sleep problems play a 
marked role. These can be severe, include insomnia, and 
are often associated with additional features such as repeti-
tive leg jerks, that is involuntary and stereotyped movements 
during sleep, the so‐called periodic limb movements during 
sleep (PLMS). Current pharmacological treatment strategies 
for RLS include dopaminergic agents (L‐Dopa or dopamine 
agonists has), α2δ calcium channel ligands, opioids, and ben-
zodiazepines, all of which, however, frequently have marked 
side effects, especially in long‐term treatment (see eg Ref.2,3). 
Whereas originally a positive response to L‐Dopa or dopa-
mine agonists was considered an additional criterion for the 
diagnosis of RLS,4 and dopamine agonists were used as first‐
line treatment, nowadays dopaminergic agents are known to 
cause augmentation and compulsive behavior.3 Sleepiness 
and weight gain are typical side effects with α2δ ligands, 
and dependency and daytime somnolence are always risks in 
treatment with opioids and benzodiazepines.
Preparations of Bryophyllum pinnatum (BP) leaves have 
been proposed to possess both sedative and muscle relaxant 
properties.5,6 Moreover, prospective observational trials per-
formed with pregnant women7 and cancer patients8 revealed 
good effectiveness in the treatment of sleep disorders with 
BP 50% chewable tablets (each 350 mg tablet corresponds to 
170 mg of leave press juice, dried down to 17 mg by mixing 
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with lactose; 100 mg dried BP matter in 1 g). Therefore, we 
set out to experimentally treat RLS patients with this herbal 
preparation.
2 |  CASE PRESENTATION
In this consecutive case series, five patients with RLS, diag-
nosed according to the updated IRLSSG consensus criteria (see 
Box ),1 and poor sleep quality documented by polysomnogra-
phy (PSG), were experimentally treated with BP preparations. 
Iron deficiency was ruled out in all patients by determining 
iron, ferritin, and transferrin levels before treatment begin. 
Brief case descriptions are presented below. The typical se-
quence of events was as follows: (a) patient presented at the 
hospital for consultation, the need for PSG for diagnostic pur-
poses was perceived, a (baseline) PSG was performed some 
weeks later; (b) baseline PSG results were communicated to 
the patient in a second consultation and further treatment was 
discussed; (c) treatment with BP was initiated unless the intro-
duction or dose adjustment of other medications was foreseen 
or the patient did not agree to taking BP preparations; (d) a sec-
ond PSG was performed 2 months after starting BP treatment 
(still under treatment). The two PSGs were scored following 
the appropriate AASM Manual,9 allowing for a comparison of 
the outcomes before and after BP treatment. Figures 1 and 2 
Box 1 Diagnostic criteria for restless legs syndrome according to Allen et al1
An urge to move the legs usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant 
sensations in the legs.
The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity 
such as lying down or sitting.
The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such 
as walking or stretching, at least as long as the activity continues.
The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in 
the evening or night than during the day.
The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral 
condition (eg myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping).
F I G U R E  1  Polysomnography records 
of patient 1, who presented with low sleep 
efficiency, before and after treatment with 
Bryophyllum pinnatum 50% tablets. LM: 
limb movements (0.5‐10 s with an increase 
of electromyogram amplitude of ≥8 µV, 
compared to electromyogram during rest); 
PLM, period limb movements (at least 
four limb movements between 0.5 and 5 s, 
recurring at intervals of 5‐90 s); [1], right 
limb; [2], left limb
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show representative examples of these pre‐/postcomparisons. 
Patients filled out several questionnaires about sleep quality 
and intensity of RLS symptoms twice: the first time during 
the first consultation or at the time point of the first PSG, and 
the second time after 2 months of BP treatment. In this way, 
the following indexes could be compared: Pittsburgh Sleep 
Quality Index, PSQI10,11; Epworth Sleepiness Scale, ESS12; 
PLMS scale from the Douglass score13; and International RLS 
Severity Scale, IRLS.14 The main results of PSG and of the 
questionnaires are depicted in Tables 1 and 2, respectively. As 
so often in daily clinical practice, some of the patients had ad-
ditional morbidities and several were taking medications; see 
Table 3 for medication overviews. One patient (patient 5) had 
a lactose intolerance. Although the amount of lactose in the 
50% chewable tablets is low in comparison with the 10‐12 g 
lactose that can be tolerated by the majority of patients with 
this intolerance,15 she did not want to take the tablets. Since 
she insisted in trying a BP preparation, we suggested she take 
a BP 33% tincture (33% of fresh plant with 45% ethanol w/w; 
final ethanol content 36% v/v; DEV 0.04:1, ie 40 mg dried 
BP matter in 1 g mother tincture; Weleda AG, Arlesheim, 
Switzerland; used in a previous study16).
2.1 | Patient 1
A 59‐year‐old woman presented with severe long‐term 
RLS after treatment with pramipexole and pregabalin, 
which had to be stopped due to side effects. At presenta-
tion, she was treated with rotigotine, a dopamine agonist 
in the form of a patch, with the additional possibility of 
taking L‐DOPA in acute phases of the disease and mag-
nesium if needed. Baseline PSG showed low sleep effi-
ciency (67%) with many arousals (22/h) and many short 
phases of wakefulness in which she frequently moved be-
cause of restlessness. During sleep, there were only few 
periodic leg movements (PLMS score 6/h) and light ob-
structive sleep apnea (apnea‐hypopnea index 7.5/h, oral 
desaturation index 8/h). She started add‐on treatment with 
BP 50% tablets at four tablets per day (0‐0‐2‐2) without 
changing other medication. As shown in Figure 1, PSG 
performed approximately 2.5 months thereafter and still 
under treatment revealed clear improvements in sleep 
architecture; sleep efficiency markedly improved (from 
67% to 90%), PLMS index was very low (1/h). In her 
subjective feedback about this recorded night, the patient 
assessed her sleep as very good. In general, the patient 
reported a marked improvement of RLS symptoms and of 
the ability to sleep, but with severe phases of restlessness 
and sleepless nights still experienced from time to time.
2.2 | Patient 2
A 65‐year‐old woman presented with severe insomnia 
and panic attacks, treated with trimipramine, a tricyclic 
F I G U R E  2  Polysomnography records 
of patient 5, who presented with frequent 
PLMS, before and after treatment with 
Bryophyllum pinnatum 33% mother tincture. 
LM: limb movements (0.5‐10 s with an 
increase of electromyogram amplitude of 
≥8 µV, compared to electromyogram during 
rest); PLM, period limb movements (at least 
four limb movements between 0.5 and 5 s, 
recurring at intervals of 5‐90 s); [1], right 
limb; [2], left limb
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antidepressant. Additionally, she was suffering from pre-
diabetes and cardiovascular disease. Baseline PSG revealed 
disturbed sleep architecture with a high prevalence of peri-
odic leg movements during sleep (PLMS index 76/h). An 
exact sleep history revealed that she suffered from restless 
legs in the evening and at night. The symptoms had started 
in late childhood and had slowly worsened over time. At the 
time of baseline PSG, RLS symptoms were quite bothering 
(IRLS 28/40). After the baseline PSG, the patient stopped 
trimipramine treatment spontaneously, which resulted in a 
reduction of RLS symptoms (IRLS decreased from 28/40 to 
20/40). Then she started treatment with BP (50% chewable 
tablets, 0‐0‐3‐3). After 2 months of BP treatment, the patient 
described a significant improvement in sleep, less suffering 
from restless legs during the early part of the night, less noc-
turnal awakening, and greater restorative value in the morn-
ing. The patient seemed to benefit markedly from treatment 
with BP. The RLS improvement perceived by the patient was 
apparent in the change of her IRLS score (from 20/40 before 
treatment down to 9/40) and in the reduction of the PLMS TA
B
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T A B L E  2  Subjective outcomes at anamnesis and approximately 
two months after start of treatment with a Bryophyllum pinnatum 
preparation per patient
 PSQIa ESSb 
Douglass score— 
PLMS scalec IRLSd 
Patient 1     
Before 12 7 28 25
After 5 6 31 20
Patient 2     
Before 9 3 25 20
After 10 0 28 9
Patient 3     
Before 13 10 33 18
After 12 11 31 17
Patient 4     
Before 4 7 12 20
After 2 4 15 2
Patient 5     
Before 14 7 27 20
After 5 5 18 10
aPSQI (Pittsburgh Sleep Quality Index, 0‐15 scale, values higher than 5 indicate 
sleep disorders10,11). 
bESS (Epworth Sleepiness Scale, 0‐24 scale, healthy persons often show values 
close to 6; values higher than 16 are indicative of a high level of daytime 
sleepiness12). 
cDouglass score—PLMS.13 In the case of patient 4, one answer needed to 
calculate the Douglass score—PLMS before starting treatment was missing and 
was replaced by the average value of the remaining score items. Since no patient 
had Douglass scores indicative of sleep apnea, narcolepsy, or psychiatric sleep 
disorder, the corresponding data are not shown. 
dIRLS (International RLS Severity Scale; 0‐40 scale; 0, none; 1‐10, mild; 11‐20, 
moderate; 21‐30, severe; 31‐40, very severe14). 
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index as calculated from the nocturnal PSG (from 76/h down 
to 41/h).
2.3 | Patient 3
A 53‐year‐old woman presented with insomnia, likely re-
lated to psychophysiological factors for which she had 
been regularly taking the benzodiazepine medication lo-
razepam at a low dose. She had had sleep problems for 
10 years and now complained of insomnia symptoms 
and was suffering from fatigue. She also suffered from 
RLS (IRLS 18/40), which had worsened under treatment 
with mirtazapine and improved with pramipexole in the 
past, but was currently not being treated. Once a week, 
she would stumble and suddenly fall down, events most 
probably caused by side effects of lorazepam. In her 
opinion, RLS complaints were not the main cause of her 
sleep disorder. During the first consultation, the patient 
was told to stop taking lorazepam, which she did. Four 
weeks later, the baseline PSG was performed, revealing 
markedly fragmented sleep architecture. Chewable tab-
lets with 50% BP (six tablets per day; 0‐0‐3‐3) were rec-
ommended to the patient. After well‐tolerated treatment 
with BP for 2 months, no major changes neither in the 
objective PSG‐outcomes (see Table 1), nor in perceived 
insomnia, or restless leg discomfort were observed. The 
patient reported, however, that the course of symptoms 
had varied markedly: During BP treatment, the falling ep-
isodes became less frequent and she was able to continue 
without taking any benzodiazepine medication, which 
she viewed positively.
2.4 | Patient 4
A 59‐year‐old man presented with severe sleep problems, 
low sleep quality, and daytime sleepiness. He did not have 
any medical history and was on no medication. PSG showed 
severely fragmented sleep architecture due to frequent pe-
riodic leg movements (PLMS score 88/h). A detailed sleep 
history revealed that he suffered from typical RLS (IRLS 
20/40). He complained about waking up frequently during 
the night and having difficulties falling asleep again because 
of a disturbing restlessness in his legs. He was not taking any 
medication. Treatment with BP (50% tablets at four tablets 
per day; 0‐0‐2‐2 tablets) was initiated. Approximately two 
months later, the patient reported significant improvements 
in night sleep, no further RLS symptoms (IRLS 2/40) and 
better restedness in the morning. Comparison of the PSG 
outputs at before and after BP treatment revealed that sleep 
efficiency had improved (from 67% up to 88%), arousals and 
waking phases during the night had decreased (arousal index 
21/h compared to 78/h before treatment), and the PLMS 
index slightly decreased (from 88/h to 73/h).
2.5 | Patient 5
A 41‐year‐old woman presented with chronic insomnia that 
had lasted for years and had become worse in the last 1.5 years. 
In addition, she had had multiple sclerosis for approximately 
9 years. About one year before, she was found to have RLS 
and her husband reported nocturnal leg movements, which 
could be PLMS. At presentation, the patient was being treated 
with the selective serotonin re‐uptake inhibitor (SSRI) citalo-
pram for previous depression. According to the patient, RLS 
symptoms appeared about five times per week, mostly be-
fore falling asleep, sometimes also during awakening (IRLS 
20/40). Her subjective sleep quality was low, which trans-
lated into a pathologically elevated PSQI; it was 12, whereas 
people without sleep disorders exhibit values up to 5. A PSG 
revealed disturbed sleep architecture, associated with a high 
PLMS index (30/h). After the PSG, BP treatment was sug-
gested. Since the patient had a lactose intolerance, she did not 
want to take the 50% chewable tablets and was offered the 
possibility of taking a BP 33% tincture, which she accepted 
(at 0‐0‐20‐20 drops per day). After 2 months’ treatment, the 
patient reported that she felt better during the day and that the 
RLS symptoms at night occurred only rarely (IRLS reduced 
from 20/40 to 10/40). This is in line with the lower PLMS 
index as measured during PSG (from 30/h to 20/h, see also 
Figure 2) and with the lower value of the PLMS scale from 
the Douglass questionnaire. Furthermore, her sleep quality 
had improved markedly (the PSQI went down to 4). When the 
T A B L E  3  Medications taken by each patient at the start of 
treatment with a Bryophyllum pinnatum preparation
Patient Medication (name, dose)
1 Acetylsalicylic acid, occasionally
 Antacid, occasionally
 L‐DOPA, 62.5 mg in acute phases of RLS only
 Magnesium, occasionally
 Rotigotine patch, 2 mg
 Tramadol, 10 drops in acute phases of RLS only
2 Amlodipine, 5 mg/d
 Bisoprolol, 2.5 mg/d
 Candesartan, 8 mg/d
 Cymarin, 30 drops/d
 Rivaroxaban, 20 mg/d
3 Doxylamine/valerian, 20 drops once per week or per 
2 wk
4 ‐
5 Citalopram, 20 mg/d
 Natalizumab, 300 mg iv every 4 wk
 Riboflavin, 200 mg/d
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patient forgot to take the BP medication (about one day every 
second week), she woke up between 2 and 3 o'clock and had 
difficulty in falling asleep again, even though she was in bed 
as usual between 11:00 pm and 6:00 am The fatigue typical for 
multiple sclerosis was still there, but the perceived tendency 
to fall asleep was less pronounced, she did not always need 
a daily nap and had more energy. After two months’ treat-
ment, the patient decided to continue to take BP 33% tincture. 
Fourteen months later, the patient was asked if she was still 
regularly taking BP 33% tincture; she was, and was still very 
positive about the effect.
3 |  DISCUSSION
Bryophyllum pinnatum (Lamarck) Oken [syn.: Kalanchoe 
pinnata (Lamarck) Persoon] is a plant of the family 
Crassulaceae. Though originally confined to Madagascar, 
BP now grows widely across tropical regions of Africa and 
America, India, China, and Australia. The plant is known 
under different common names, such as life plant, air plant, 
love plant, Cathedral bells, and Goethe plant. Leaf extracts 
from BP have been used in traditional medicine of the regions 
where it grows and are supposed to have, among other things, 
sedative and muscle relaxant properties.17,18 In Europe, BP 
started to be used at the beginning of the 20th century in an-
throposophic medicine, a form of holistic medicine with an 
integrative approach.19 The indications for which BP is often 
used within this type of medicine and more recently also in 
conventional settings include preterm labor, overactive blad-
der, and sleep disorders.5,6 Several retrospective5,20 and a 
few prospective studies on the treatment of preterm contrac-
tions16,21 and of overactive bladder22 with BP preparations 
have been performed and suggest good effectiveness and very 
good safety/tolerability. The data are in line with the relaxant 
effects of BP preparations that have been observed in in vitro 
models, admittedly on smooth muscle, myometrium,23,24 or 
detrusor.25,26 Prospective observational studies have also 
revealed positive effects on sleep quality, both during preg-
nancy7 and among cancer patients.8 These clinical data are 
corroborated by in vivo experiments showing that different 
fractions of the leaf extract of BP can prolong the pentobarbi-
tone‐induced sleeping time, indicating a CNS depressant ac-
tion.27 This neurosedative effect could later be confirmed in a 
second study, which also revealed muscle relaxant effects.18 
Some of the bufadienolides present in Bryophyllum species 
are thought to be responsible for the sedative effects.28,29
The physician Willis first described a patient with RLS 
symptoms in 1685, while Ekbom used the term restless legs 
syndrome for the first time in 1945; therefore, RLS is also 
known as Willis‐Ekbom disease. The highly complex and 
even surprising pathophysiology of RLS (ICD‐10‐CM code: 
G25.81) has still not been fully elucidated. Genetic factors 
as well as elements of iron and dopamine neurotransmit-
ter pathophysiology play major roles.30 It is assumed that 
regional brain iron deficiency activates hypoxic pathways, 
which in turn leads to increased dopaminergic activity and 
eventually to postsynaptic down‐regulation either at the re-
ceptor and/or at intracellular level. This latter postsynaptic 
deficit, together with the marked circadian dopamine activity 
pattern, triggers the typical RLS symptoms predominantly in 
the evening or at night. It is therefore understandable that a 
disturbed sleep profile and response to dopaminergic agents 
support the diagnosis of RLS. Also, PMLS and a positive 
familial history are supportive of this diagnosis. Prevalence 
rates lie between 3% and 12%.2,31 Women are more affected 
than men are, especially during pregnancy, when prevalence 
is 2‐3 times greater than in the general population.31,32 While 
first‐line agents such as dopamine agonists and α2δ cal-
cium channel ligands relieve RLS, pronounced side effects 
can prevent their further (long‐term) use. Dopaminergic 
augmentation requires particular attention, as may be sur-
mised from the pathophysiology described above and from 
the complex long‐term therapy algorithm that was recom-
mended by a combined task force of various RLS‐related 
organizations.3 Therefore, alternative therapies are required. 
Several RLS features hamper treatment as well as the per-
formance of clinical trials: (a) subjective assessment (how 
patients perceive the severity of their symptoms) may dif-
fer from the objective outcomes, for example PSG, (b) dis-
continuity of symptoms (there are sporadic daily changes in 
symptom intensity and many patients report singular phases 
of more or less severe symptoms), and (c) possible placebo 
effects. A meta‐analysis revealed an average placebo re-
sponse rate of 40% in RLS trials. In this work, the highest 
placebo effect size was found for IRLS. However, for PLMS, 
the placebo effect was small, and for sleep efficiency, it was 
nearly absent.33
Our observations, obtained while experimentally treat-
ing five RLS patients with BP preparations, suggest that four 
patients have benefited from the treatment, albeit in different 
ways. The present consecutive case series was initiated because 
an improvement in sleep quality was to be expected on the basis 
of previous prospective observational studies.7,8 Indeed, several 
improvements in sleep‐related outcomes were observed in this 
series. The pre‐/postcomparison of the PSGs reveals that the 
patients with low sleep efficiency (patient 1, female, and pa-
tient 4, male), moderate sleep latency (patient 5, female), and 
high arousal index (patient 4, male) at treatment begin could 
show improvement for these sleep parameters. The disease 
course of patient 4, who presented with severe sleep problems 
and restless legs symptoms, deserves to be highlighted. He was 
the only male patient in this prospective case series, was tak-
ing no additional medications, and showed marked objective 
improvement under BP. This included improvement of sleep 
efficiency (from 67% up to 88%) and fewer arousals (from 
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78/h to 21/h). Arousals reduction, which can be interpreted 
as a positive effect on sleep stability, was shown to occur in 
the course of RLS treatment with the benzodiazepine clonaze-
pam.34 This strengthens earlier suggestions of the GABAergic 
effects of (some) BP components,28,29 but future experimental 
research and randomized clinical trials would be required to 
confirm them. Interestingly, the patient who did not show im-
provements either in RLS symptoms or in sleep quality (num-
ber 3, female) was able to abstain from benzodiazepines. This 
favorably affected her health status, but rather due to benefiting 
from sedation without adverse events. Surprisingly, but in line 
with the previously described muscle relaxant effects of BP 
preparations, lowering the frequency of PLMS was observed 
in four out of five patients, most interestingly, also in the two 
patients with the highest PLMS indexes (patient 2, female, and 
patient 4, male). In general, analysis of the questionnaires filled 
out by the patients (mainly items used to calculate PSQI and 
IRLS) and patients’ feedback supported those pre‐/postcompar-
isons of the PSGs. Taken together, the results of the present 
case series show that BP seems, as expected, to trigger sedative 
effects (several improvements in sleep‐related outcomes, fewer 
arousals), but also to cause some relaxing effects (fewer RLS 
symptoms, fewer periodic leg movements in sleep). Four out of 
the five patients showed relevant reductions of RLS symptoms, 
as was apparent in lower IRLS, an index that has been used as 
the gold‐standard outcome measure for clinical trials and was 
found to fulfill the criteria for “recommended” instruments to 
assess the severity of RLS symptoms (both in the practice set-
ting and in clinical trials).14
In view of the present paucity of well‐tolerated and long‐
term unproblematic treatments for RLS, our observations sug-
gest that it might be worthwhile to treat RLS patients with 
(add‐on) BP preparations. These might be particularly indicated 
in the treatment of (frequent) RLS during pregnancy—espe-
cially if iron substitution is not needed or not enough—since 
the standard RLS medications are contra‐indicated in preg-
nancy35 and BP preparations are already recommended36 and 
in use for other indications.21 In a recent prospective obser-
vational study performed to assess BP prescriptions in the 
field of gynecology and obstetrics in Switzerland, one case 
showing a very good effect of BP medication on RLS during 
pregnancy was described.21 Moreover, several clinical trials 
revealed good tolerability during pregnancy.7,16,20
The main limitations of this case series are the heterogene-
ity of the patients, which potentially introduces a number of 
confounding factors, and the low number of PSGs performed 
for each patient (one before treatment and one thereafter). 
Given the variability of several RLS parameters from night 
to night, for example three PSG recordings at each occasion 
would have delivered more trustworthy results. Moreover, 
and in view of the patient collective, we had to depart from 
our original goal of including only patients without co‐medi-
cations in this case series, that is including patients who were 
not planning to change their medications. The co‐medica-
tions of four patients (only patient 4 was drug‐naïve) can be 
seen as an additional limitation. In the case of patient 2, the 
baseline PSG was performed still under trimipramine, a tricy-
clic antidepressant, which is presumed to worsen RLS 37; the 
BP contribution to the improvements of the PSG‐outcomes 
might therefore be overestimated.
The present case series shows that treatment of RLS with 
BP preparations deserves further clinical investigations and at 
the same time reveals several aspects to be considered in plan-
ning prospective efficacy trials with high patient numbers. The 
reduction of IRLS in four out of five patients suggests that this 
outcome is a valuable tool in assessing BP effects. Also, PSQI 
could be the appropriate tool for assessing changes in sleep 
quality in patients with RLS: In two patients, a clear‐cut PSQI 
reduction was observed that was even superior to that seen in 
the earlier prospective study on cancer patients (from 12 to 
9 during 3‐week treatment8). Objective PLMS assessment in 
a prospective trial with ankle‐actigraphy would be an ideal, 
but straightforward, complement to IRLS and PSQI indexes. 
Since some effects might not be assessed with these two in-
dexes, a (health‐related) quality of life questionnaire might be 
a useful complement. Finally, a trial on BP as an add‐on medi-
cation for RLS (in the absence of pregnancy) as well as one on 
BP as a single medication for pregnancy‐related RLS appears 
promising. In both cases, a solution for patients reluctant to 
ingest lactose might be worthwhile.
4 |  CONCLUSION
The disease courses of four out of our five patients suggest 
that RLS treatment with BP preparations (mainly chewable 
tablets, or the lactose‐free alternative, 33% mother tincture) 
can improve RLS and sleep quality in patients with RLS. 
Spasmolytic properties and the sedative effect of BP prepara-
tions seem to play a role. Given its excellent profile in terms 
of side effects, BP could also be used in pregnant women with 
RLS, where nonmedication treatment is considered primary 
if no iron treatment is needed or iron treatment alone is not 
successful. Prospective observational studies with high patient 
numbers and longer treatment duration are urgently needed.
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